Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Caribou Biosciences' Non-Current Deffered Revenue fell 55.51% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 55.51%. This contributed to the annual value of $3.3 million for FY2024, which is 45.64% down from last year.
  • Caribou Biosciences' Non-Current Deffered Revenue amounted to $1.8 million in Q3 2025, which was down 0.90% from $1.8 million recorded in Q2 2025.
  • Caribou Biosciences' Non-Current Deffered Revenue's 5-year high stood at $24.2 million during Q2 2021, with a 5-year trough of $1.8 million in Q3 2025.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $4.6 million (2024), whereas its average is $6.2 million.
  • In the last 5 years, Caribou Biosciences' Non-Current Deffered Revenue surged by 2,251.33% in 2021 and then tumbled by 74.65% in 2024.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Non-Current Deffered Revenue stood at $22.0 million in 2021, then decreased by 27.59% to $16.0 million in 2022, then crashed by 61.75% to $6.1 million in 2023, then crashed by 45.64% to $3.3 million in 2024, then slumped by 55.51% to $1.8 million in 2025.
  • Its Non-Current Deffered Revenue stands at $1.8 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.6 million for Q1 2025.